Fernwood Investment Management LLC maintained its position in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) during the second quarter, Holdings Channel reports. The institutional investor owned 8,142 shares of the biopharmaceutical company’s stock at the end of the second quarter. Fernwood Investment Management LLC’s holdings in Sage Therapeutics were worth $648,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the stock. FMR LLC increased its position in shares of Sage Therapeutics by 0.3% in the first quarter. FMR LLC now owns 5,590,527 shares of the biopharmaceutical company’s stock valued at $397,319,000 after buying an additional 15,451 shares in the last quarter. BlackRock Inc. increased its position in shares of Sage Therapeutics by 10,082.5% in the first quarter. BlackRock Inc. now owns 2,863,124 shares of the biopharmaceutical company’s stock valued at $203,482,000 after buying an additional 2,835,006 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Sage Therapeutics by 10.8% in the first quarter. Vanguard Group Inc. now owns 2,691,275 shares of the biopharmaceutical company’s stock valued at $191,269,000 after buying an additional 261,759 shares in the last quarter. Bank of New York Mellon Corp increased its position in shares of Sage Therapeutics by 189.3% in the first quarter. Bank of New York Mellon Corp now owns 2,056,895 shares of the biopharmaceutical company’s stock valued at $146,183,000 after buying an additional 1,345,829 shares in the last quarter. Finally, Palo Alto Investors LLC increased its position in shares of Sage Therapeutics by 9.1% in the first quarter. Palo Alto Investors LLC now owns 1,101,951 shares of the biopharmaceutical company’s stock valued at $78,316,000 after buying an additional 92,021 shares in the last quarter.

Sage Therapeutics, Inc. (NASDAQ:SAGE) opened at 84.79 on Wednesday. The company’s market cap is $3.17 billion. Sage Therapeutics, Inc. has a 12-month low of $35.02 and a 12-month high of $90.43. The firm has a 50 day moving average price of $81.90 and a 200 day moving average price of $71.00.

Sage Therapeutics (NASDAQ:SAGE) last posted its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($1.88) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.63) by $0.25. During the same period in the prior year, the business posted ($1.08) EPS. On average, analysts anticipate that Sage Therapeutics, Inc. will post ($7.38) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Fernwood Investment Management LLC Maintains Stake in Sage Therapeutics, Inc. (SAGE)” was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at https://www.watchlistnews.com/fernwood-investment-management-llc-maintains-stake-in-sage-therapeutics-inc-sage/1494495.html.

SAGE has been the subject of several analyst reports. ValuEngine upgraded Sage Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Cowen and Company initiated coverage on Sage Therapeutics in a research report on Monday, June 12th. They set an “outperform” rating and a $95.00 price objective for the company. BMO Capital Markets reiterated a “buy” rating and set a $82.00 price objective on shares of Sage Therapeutics in a research report on Friday, July 28th. Stifel Nicolaus reiterated a “buy” rating and set a $90.00 price objective on shares of Sage Therapeutics in a research report on Friday, July 14th. Finally, Leerink Swann reiterated an “outperform” rating and set a $97.00 price objective (up from $90.00) on shares of Sage Therapeutics in a research report on Tuesday, June 20th. Four investment analysts have rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $89.64.

About Sage Therapeutics

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Want to see what other hedge funds are holding SAGE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sage Therapeutics, Inc. (NASDAQ:SAGE).

Institutional Ownership by Quarter for Sage Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.